Richard S Finkel

39PUBLICATIONS
153CO-AUTHORS
Neurology and neuromuscular diseasesGene and molecular therapyNeural engineeringMedical roboticsCraniofacial biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 17, 2026
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.

|Jun 10, 2026
Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.

|Feb 03, 2026
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Richard S Finkel, Thomas O Crawford, Eugenio Mercuri

|Dec 08, 2025
Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Crystal M Proud, Dũng Chí Vũ, Jo M Wilmshurst

|Nov 11, 2025
Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry.

Yasemin Erbaş, Laurent Servais, Perry B Shieh

|Oct 25, 2025
Real-world evidence on nusinersen treatment of persons with SMA: a focused review.

Susan E Matesanz, Richard S Finkel

Pageof 7

Frequent Collaborators

8 joint publications

Francesco Muntoni

7 joint publications

Davide Pareyson

5 joint publications

Jacqueline Montes

5 joint publications

Chiara Pisciotta